case_images: PMC5422723_01
case_images: Plain X-ray and cerebral MRI (T1-weighted image). a Plain chest X-ray of patient 1 before vemurafenib: a metastatic lesion is detected in her left lung. b Plain chest X-ray of patient 1 after vemurafenib: the size of the metastatic lesion is reduced to approximately half. c Patient 1: 3 months after starting vemurafenib therapy, several brain metastases are present in the occipital lobe (yellow arrowheads). d Patient 1: 3 months later (i.e. 6 months after starting vemurafenib therapy), the metastatic tumors have grown rapidly despite vemurafenib therapy. e Patient 2: 4 months after starting vemurafenib therapy, several brain metastases are present in the occipital lobe. f Patient 2: 4 months later (i.e. 8 months after starting vemurafenib therapy), the metastatic tumors have grown rapidly. g Patient 3: hyperintensity was detected on the surface of the right temporal lobe.
case_images: cro-0010-0290-g01.jpg
case_images: PMC5422723_03_cro-0010-0290-g01.jpg
case_images: F1
case_images: MRI scans revealed meningeal seeding (LDH was 240, Fig. 1g), whereas the patient's other metastatic lesions appeared to be reduced on computed tomography.
case_images: PMC5422723_02
case_images: Plain X-ray and cerebral MRI (T1-weighted image). a Plain chest X-ray of patient 1 before vemurafenib: a metastatic lesion is detected in her left lung. b Plain chest X-ray of patient 1 after vemurafenib: the size of the metastatic lesion is reduced to approximately half. c Patient 1: 3 months after starting vemurafenib therapy, several brain metastases are present in the occipital lobe (yellow arrowheads). d Patient 1: 3 months later (i.e. 6 months after starting vemurafenib therapy), the metastatic tumors have grown rapidly despite vemurafenib therapy. e Patient 2: 4 months after starting vemurafenib therapy, several brain metastases are present in the occipital lobe. f Patient 2: 4 months later (i.e. 8 months after starting vemurafenib therapy), the metastatic tumors have grown rapidly. g Patient 3: hyperintensity was detected on the surface of the right temporal lobe.
case_images: cro-0010-0290-g01.jpg
case_images: PMC5422723_03_cro-0010-0290-g01.jpg
case_images: F1
case_images: MRI scans revealed meningeal seeding (LDH was 240, Fig. 1g), whereas the patient's other metastatic lesions appeared to be reduced on computed tomography.
case_images: PMC5422723_03
case_images: Plain X-ray and cerebral MRI (T1-weighted image). a Plain chest X-ray of patient 1 before vemurafenib: a metastatic lesion is detected in her left lung. b Plain chest X-ray of patient 1 after vemurafenib: the size of the metastatic lesion is reduced to approximately half. c Patient 1: 3 months after starting vemurafenib therapy, several brain metastases are present in the occipital lobe (yellow arrowheads). d Patient 1: 3 months later (i.e. 6 months after starting vemurafenib therapy), the metastatic tumors have grown rapidly despite vemurafenib therapy. e Patient 2: 4 months after starting vemurafenib therapy, several brain metastases are present in the occipital lobe. f Patient 2: 4 months later (i.e. 8 months after starting vemurafenib therapy), the metastatic tumors have grown rapidly. g Patient 3: hyperintensity was detected on the surface of the right temporal lobe.
case_images: cro-0010-0290-g01.jpg
case_images: PMC5422723_03_cro-0010-0290-g01.jpg
case_images: F1
case_images: MRI scans revealed meningeal seeding (LDH was 240, Fig. 1g), whereas the patient's other metastatic lesions appeared to be reduced on computed tomography.